FMTX - Forma plunges after updated early-stage data for sickle cell disease therapy

Chan2545/iStock via Getty Images Forma Therapeutics ([[FMTX]] -20.9%) is trading sharply lower in morning hours after the company announced new data from its ongoing Phase 1 trial of etavopivat (formerly referred to as FT-4202) in patients with sickle cell disease ((SCD)). The results being presented at the 26th Annual European Hematology Association ((EHA)) 2021 included initial data from the open-label extension ((OLE)) cohort and unblinded results from the two multiple ascending dose ((MAD)) cohorts.  In the combined MAD1 (300 mg QD) and MAD2 (600 mg QD) cohorts, 73% (11 of 15) of patients achieved a hemoglobin increase of greater than 1g/dL over the baseline, the company said. As of May 24, 2021, in the OLE cohort of eight patients, there was a hemoglobin increase of more than 1 g/dL in 88% (7 of 8), with a mean hemoglobin increase of 1.5 g/dL after the treatment etavopivat (400 mg QD) for at least

For further details see:

Forma plunges after updated early-stage data for sickle cell disease therapy